Journal

Metabolic medicine

Does Hormone Therapy Make Your GLP-1 Medication Work Even Better?

A 2026 Mayo Clinic study in The Lancet found postmenopausal women who paired hormone therapy with tirzepatide lost 35% more total body weight than women on tirzepatide alone. Here's what that means for you.

August 20, 2026

Short answer: it looks that way. A 2026 Mayo Clinic study, published in The Lancet, found that postmenopausal women who paired hormone therapy with the GLP-1 medication tirzepatide lost 35% more total body weight than women taking tirzepatide alone.
19.2%
HORMONE THERAPY + TIRZEPATIDE
14.0%
TIRZEPATIDE ALONE

Average total body weight lost over ~18 months · statistically significant (p=0.0023)

If you’re in your 40s or 50s, doing everything “right,” and still watching the scale — and your training numbers — move the wrong way, this research validates something a lot of women have suspected for years: menopause doesn’t just change how you feel, it can change how your body responds to weight-loss treatment, too.

Why this happens in perimenopause & menopause

Muscle loss slows metabolism

Lean muscle drops faster after menopause, which lowers your resting metabolic rate.

Fat storage shifts to your belly

Visceral fat grows about 6% a year during menopause, versus roughly 1% a year before it.

Sleep gets disrupted

Hot flashes and night sweats affect 70–80% of women here, throwing off appetite hormones.

None of this is a willpower problem. It’s biology.

What Mayo Clinic researchers found

Published in The Lancet Obstetrics, Gynaecology & Women’s Health, February 2026

Researchers closely matched 40 postmenopausal women using hormone therapy alongside tirzepatide to 80 women on tirzepatide alone — same age, BMI, and health profile. The two groups looked statistically identical at the start, which makes the difference in outcomes meaningful.

Lost 20% or more of body weight~2× more likely
Hormone therapy
45%
Tirzepatide alone
24%
Lost 25% or more of body weight~4× more likely
Hormone therapy
28%
Tirzepatide alone
8%
Lost 30% or more of body weight~4× more likely
Hormone therapy
18%
Tirzepatide alone
4%

Interesting twist: at more modest goals (5–15% weight loss), both groups did about the same. The hormone-therapy advantage shows up specifically at the harder-to-reach milestones — all differences above are statistically significant (p<0.05).

Beyond the scale

  • Blood pressure and blood sugar improved in both groups.
  • Cholesterol trended steadier with combined therapy.
  • Similar, mostly mild side effects in both groups (32% vs. 43%).

Is this right for you?

This was an observational study, not a randomized trial — so it shows a strong association, not proof of cause. It’s also a smaller, single-system study, and hormone therapy isn’t the right fit for every woman; it carries its own risks that deserve a real conversation with a physician who knows your full history. What this data does tell us: if you already have a reason to consider hormone therapy — like hot flashes or disrupted sleep — it may be worth discussing alongside your weight-loss plan, not instead of it.

Vital Coeur Health

You deserve to feel empowered, not powerless.

Navigating GLP-1 and hormone therapy shouldn’t happen through an app questionnaire or a single-symptom telehealth visit. At Vital Coeur, your physician looks at your full picture — hormones, metabolic labs, training, and goals — and builds one coordinated plan. We’re here to help you navigate the process and get you feeling like yourself again.

Book a Discovery Call →

Source: Castaneda R, et al. “The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study.” Lancet Obstet Gynaecol Womens Health 2026;2:e118–e128. This article is for educational purposes and is not a substitute for individualized medical advice. Talk to your physician before starting or changing any hormone therapy or weight-management medication.